publication date: Mar. 18, 2016

Senate Bill Gives FDA More Control Over Its Hiring, Salaries and Structure


The FDA and NIH Workforce Authorities Modernization Act was introduced in the Senate by Republican and Democratic leaders of the health committee. The bill aims to help FDA and NIH “attract top talent during this exciting time in science.”

The bill, introduced by Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.), looks to improve coordination within and between FDA medical product centers and allow the FDA to update its structure, as well as make it easier for the agency to hire; improve access to scientific meetings for federal employees; and streamline processes for NIH research information collection.

“With so many patients and families waiting and hoping for new, safe, effective cures and treatments, we should absolutely work to strengthen hiring practices and break down siloed research that get in the way of innovation,” said Murray. “I’m pleased that the committee has reached agreement on legislation to help ensure the FDA and NIH are able to keep the best researchers, doctors and scientists on staff, and to break down barriers that may impede important collaboration. I’m very hopeful that we can continue working in a bipartisan way to agree on strong mandatory investments in the NIH and the FDA as well as policies to strengthen patient and consumer safety—each of which, as Democrats have made clear, are necessary to reach a final agreement.”

The bill allows the FDA to conduct a pilot program to test the best ways to boost communication between different centers at the … Continue reading 42-11 Senate Bill Gives FDA More Control Over Its Hiring, Salaries and Structure

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.